Press Release
« Back
Celldex's CDX-301 in Combination with Mozobil(R) Increases Hematopoietic Stem Cell Mobilization and Results in Improved Transplantation of Mobilized Cells in Preclinical Studies; Results Presented at ASH 2013
Dec 10, 2013
"We need novel interventions to advance hematopoietic stem cell mobilization techniques and transplantation, and based on our studies to date, this could be a promising alternative approach for these patients," said
"The data presented today further demonstrate the potential for CDX-301 to improve both autologous and allogeneic hematopoietic stem cell transplantation and, importantly, show the ability for CDX-301 to combine effectively with other cell mobilization agents," said
Current standard of care mobilization treatments produce grafts, or transplanted tissues, that may not contain sufficient numbers of hematopoietic stem cells or may cause graft-versus-host disease (GVHD), a common complication following allogeneic transplantation in which the immune cells in the graft recognize the host, or recipient, as foreign and react by attacking the host's cells. This study found that the combination of CDX-301 and Mozobil® mobilized the highest rate and amount of hematopoietic stem cells into peripheral blood compared to the mice treated with granulocyte colony-stimulating factor (G-CSF, an
Mozobil® is a registered trademark of Genzyme Corporation.
About CDX-301
CDX-301 or Flt3L is a potent hematopoietic cytokine currently in Phase 1 development that stimulates the expansion and differentiation of hematopoietic progenitor and stem cells. Flt3L has demonstrated a unique capacity to increase the number of circulating dendritic cells in both laboratory and clinical studies. In addition, Flt3L has shown impressive results in models of cancer, infectious diseases and inflammatory/autoimmune diseases. Celldex believes this ligand may hold significant opportunity for synergistic development in combination with other proprietary molecules in the Company's portfolio.
About
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Company's strategic focus and the future development and commercialization (by Celldex and others) of rindopepimut (CDX-110), glembatumumab vedotin ("glemba"; CDX-011), CDX-1135, CDX-1401, CDX-1127, CDX-301, Belinostat and other products. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of rindopepimut, glembatumumab vedotin and other drug candidates, our ability to obtain additional capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; our ability to adapt our APC Targeting TechnologyTM to develop new, safe and effective vaccines against oncology and infectious disease indications; our ability to successfully complete product research and further development of our programs; the uncertainties inherent in clinical testing; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage research and development efforts for multiple products at varying stages of development; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:Source:Sarah Cavanaugh Vice President of Investor Relations& Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 scavanaugh@celldex.com
News Provided by Acquire Media